Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
Head and Neck Cancer
Watch Time: 2 mins

Jean-Pascal Machiels, ESMO 2022: Highlights in head and neck cancer

Share this Video
Copy Link
Published Online: Sep 14th 2022

Dr Jean-Pascal Machiels (Cliniques Universitaires Saint-Luc, Brussels, Belgium) joins touchONCOLOGY to discuss clinical trial highlights in head and neck cancer presented at EMSO 2022.

Questions:

  1. What are the hot topics and highlights in head and neck cancers from ESMO 2022?

Disclosures: Jean-Pascal Machiels is an Advisory board member or speaker with honoraria (managed by my Institution) for Pfizer, Roche, Astra/Zeneca, Bayer, Innate, Merck Serono, Boerhinger, BMS, Novartis, Janssen, Incyte, Cue Biopharma, ALX Oncology, iTEOS, eTheRNA, NEKTAR, F-Star. He receives travel expenses from Amgen, BMS, Pfizer, MSD, and Gilead; is on the data safety monitoring board with honoraria for Psioxus; has an institutional conflict of interest (Funding to institution for research support) with all companies above; has an uncompensated advisory role at MSD; and is the EORTC investigator and study coordinator, and H & N group Chair.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Filmed in coverage of ESMO 2022

Access more head and neck cancer content here

Related Videos In Head and Neck Cancer
Head and Neck Cancer
Developed by Touch
Makoto Tahara, ESMO 2022: 5-year results from KEYNOTE-048 – Pembrolizumab for treatment of recurrent/metastatic head and neck squamous cell carcinoma
Watch Time: 4 mins

Long-term follow-up (4 years) of the phase 3 KEYNOTE-048 (NCT02358031) study continued to demonstrate survival benefit with pembrolizumab monotherapy and pembrolizumab + chemotherapy vs EXTREME in first-line recurrent/metastatic head and neck squamous cell carcinoma. Dr Makoto Tahara(Cliniques Universitaires Saint-Luc, Brussels, Belgium) joins touchONCOLOGY to discuss 5 years of follow-up in patients from KEYNOTE-048, and the […]

Head and Neck Cancer
Developed by Touch
Jean-Pascal Machiels, ESMO 2022: Phase 3 KEYNOTE-412 study – efficacy and safety of pembrolizumab + chemoradiation therapy in locally advanced head and neck squamous cell carcinoma

Pembrolizumab is currently approved as monotherapy or in combination with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma. Dr Jean-Pascal Machiels (Cliniques Universitaires Saint-Luc, Brussels, Belgium) joins touchONCOLOGY to discuss the current limitations in treatment options, and the phase 3 KEYNOTE-412 study investigating the efficacy and safety of pembrolizumab + chemoradiation therapy (CRT) vs […]

Head and Neck Cancer
Developed by Touch
Jean-Pascal Machiels, ESMO 2022: Highlights in head and neck cancer
Watch Time: 2 mins

Dr Jean-Pascal Machiels (Cliniques Universitaires Saint-Luc, Brussels, Belgium) joins touchONCOLOGY to discuss clinical trial highlights in head and neck cancer presented at EMSO 2022. Questions: What are the hot topics and highlights in head and neck cancers from ESMO 2022? Disclosures: Jean-Pascal Machiels is an Advisory board member or speaker with honoraria (managed by my […]

Trending In Head and Neck Cancer:

Makoto Tahara, ESMO 2022: 5-year results from KEYNOTE-048 – Pembrolizumab for treatment of recurrent/metastatic head and neck squamous cell carcinoma
Head and Neck Cancer
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72